Global Ulcerative Colitis Market
Market Size in USD Million
CAGR :
% 
USD
7,321.78 Million
USD
10,792.98 Million
2023
2030
 Forecast Period |
2024 –2030 |
 Market Size (Base Year) |
USD 7,321.78 Million |
 Market Size (Forecast Year) |
USD 10,792.98 Million |
 CAGR |
% |
| Major Markets Players |
|
Global Ulcerative Colitis Market, By Type (Ulcerative Proctitis, Proctosigmoiditis, Left-Sided Colitis, Pan Colitis or Universal Colitis, and Fulminant Colitis), Drug Type (Anti-Inflammatory Drugs, Amino salicylates, Corticosteroids, Anti-TNF biologics, Immunosuppressant, Calcineurin Inhibitors and Other), Molecule Type (Small Molecules and Biologics), Route of Administration (Injectable and Oral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Store and Others) - Industry Trends and Forecast to 2030.
Ulcerative Colitis Market Analysis and Size
Ulcerative colitis is a chronic disease that directly affects the large intestine or colon. Ulcerative colitis is a disease characterized by inflammation of the large intestine resulting in abdominal pain, blood in stool, and diarrhea.
Data Bridge Market Research analyses that the global ulcerative colitis market which was USD 7,321.78 million in 2023, would rocket up to USD 10,792.98 million by 2030, and is expected to undergo a CAGR of 5.7% during the forecast period. This indicates that the market value. "Multivitamin" dominates the product type segment of the global ulcerative colitis market due to increasing awareness about ulcerative colitis. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Ulcerative Colitis Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015-2020) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Type (Ulcerative Proctitis, Proctosigmoiditis, Left-Sided Colitis, Pan Colitis or Universal Colitis, and Fulminant Colitis), Drug Type (Anti-Inflammatory Drugs, Amino salicylates, Corticosteroids, Anti-TNF biologics, Immunosuppressant, Calcineurin Inhibitors and Other), Molecule Type (Small Molecules and Biologics), Route of Administration (Injectable and Oral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Store and Others) |
|
Countries Covered |
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa |
|
Market Players Covered |
Johnson & Johnson Services, Inc. (U.S.), Bayer AG (Germany), AbbVie Inc. (U.S.), Merck & Co., Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), GlaxoSmithKline plc. (UK), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (U.S.), Abbott (U.S.), Astrazeneca (UK), Sanofi (France), Allergan (Ireland), CELGENE CORPORATION (U.S.), Bristol-Myers Squibb Company (U.S.), InDex Pharmaceuticals Holding AB (Sweden), among others. |
|
Market Opportunities |
|
Market Definition
Ulcerative colitis is a chronic inflammatory bowel disease (IBD) that primarily affects the colon (large intestine) and rectum. It is characterized by inflammation and ulcers in the inner lining of the digestive tract. The exact cause of ulcerative colitis is not fully understood, but it is believed to involve a combination of genetic, environmental, and immune system factors.
Global Ulcerative Colitis Market Dynamics
Drivers
- Increasing Prevalence and Incidence
The prevalence and incidence of ulcerative colitis have been rising globally. The disease affects millions of individuals worldwide, and the numbers continue to increase, particularly in developed countries. This growing patient population drives the demand for effective treatments and healthcare services, thus fuelling the growth of the ulcerative colitis market.
- Increasing Awareness and Diagnosis
Improved awareness of ulcerative colitis among healthcare professionals and the general population has led to early detection and diagnosis of the disease. As awareness increases, more individuals with symptoms seek medical attention, leading to timely diagnosis and initiation of treatment. This trend contributes to the expansion of the ulcerative colitis market.
- Growing Healthcare Expenditure
Increased healthcare expenditure worldwide, particularly in developing economies, supports the growth of the ulcerative colitis market. With greater financial resources allocated to healthcare, there is an increased focus on providing access to quality care, including diagnosis, treatment, and management of chronic diseases like ulcerative colitis.
Opportunities
- Advancements in Medical Research
Ongoing research and developments in the understanding of ulcerative colitis have led to advancements in diagnostic tools, treatment options, and therapeutic approaches. This includes the introduction of novel medications, biological therapies, and targeted treatments that aim to provide more effective management of the disease. These advancements attract investments, drive innovation, and contribute to the growth of the market.
Restraints/Challenges
- Regulatory Challenges
Obtaining regulatory approvals for new ulcerative colitis drugs involves rigorous testing and evaluation processes. These regulatory hurdles can significantly delay the launch of new drugs, increasing development costs and limiting the market entry of innovative treatments. Adhering to these regulations and obtaining necessary approvals can be time-consuming and costly, hindering market growth.
This Ulcerative colitis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Ulcerative colitis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In December 2022, Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for etrasimod for individuals living with moderately-to-severely active ulcerative colitis (UC).
Global Ulcerative Colitis Market Scope
The Ulcerative colitis market is segmented on the basis of type, drug type, molecule type, route of administration, and distribution channel. The growth amongst these segments will help you meagre growth segments in the industries and provide the users with a valuable market overview and insights to help them make strategic decisions for identifying core market applications.
Type
- Ulcerative Proctitis
- Proctosigmoiditis
- Left-Sided Colitis
- Pan Colitis or Universal Colitis
- Fulminant Colitis
Drug Type
- Anti-Inflammatory Drugs
- Amino salicylates
- Corticosteroids
- Anti-TNF biologics
- Immunosuppressant
- Calcineurin Inhibitors
- Other
Molecule Type
- Small Molecules
- Biologics
Route of Administration
- Injectable
- Oral
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Drug Store
- Others
Global Ulcerative Colitis Market Regional Analysis/Insights
The global ulcerative colitis market is analysed and market size insights and trends are provided by country, type, drug type, molecule type, route of administration, and distribution channel, as referenced above.
The countries covered in the global ulcerative colitis market report is U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Rest of Middle East & Africa.
North America is expected to dominate the global ulcerative colitis market due to the increasing prevalence of ulcerative colitis in that region. Asia-Pacific is expected to be the fastest growing region due to increasing rising awareness about ulcerative colitis.
The country section of the report also provides individual market impacting factors and domestic regulation changes that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The ulcerative colitis market also provides you with a detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for the ulcerative colitis market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the ulcerative colitis market. The data is available for the historic period 2015-2020.
Competitive Landscape and Ulcerative Colitis Market Share Analysis
The ulcerative colitis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to ulcerative colitis market.
Some of the major players operating in the ulcerative colitis market are:
- Johnson & Johnson Services, Inc. (U.S.)
- Bayer AG (Germany)
- AbbVie Inc. (U.S.)
- Merck & Co., Inc. (U.S.)
- Takeda Pharmaceutical Company Limited (Japan)
- GlaxoSmithKline plc. (UK)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Pfizer Inc. (U.S.)
- Abbott (U.S.)
- Astrazeneca (UK)
- Sanofi (France)
- Allergan (Ireland)
- CELGENE CORPORATION (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- InDex Pharmaceuticals Holding AB (Sweden)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL ULCERATIVE COLITIS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL ULCERATIVE COLITIS MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL ULCERATIVE COLITIS MARKET : RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES MODEL
5 INDUSTRY INSIGHTS
5.1 PATENT ANALYSIS
5.1.1 PATENT LANDSCAPE
5.1.2 USPTO NUMBER
5.1.3 PATENT EXPIRY
5.1.4 EPIO NUMBER
5.1.5 PATENT STRENGTH AND QUALITY
5.1.6 PATENT CLAIMS
5.1.7 PATENT CITATIONS
5.1.8 PATENT LITIGATION AND LICENSING
5.1.9 FILE OF PATENT
5.1.10 PATENT RECEIVED CONTRIES
5.1.11 TECHNOLOGY BACKGROUND
5.2 DRUG TREATMENT RATE BY MATURED MARKETS
5.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
5.4 PATIENT FLOW DIAGRAM
5.5 KEY PRICING STRATEGIES
5.6 KEY PATIENT ENROLLMENT STRATEGIES
5.7 INTERVIEWS WITH SPECIALIST
5.8 OTHER KOL SNAPSHOTS
6 EPIDEMIOLOGY
6.1 INCIDENCE OF ALL BY GENDER
6.2 TREATMENT RATE
6.3 MORTALITY RATE
6.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
6.5 PATIENT TREATMENT SUCCESS RATES
6.6 INCIDENCE RATE, BY INFLAMMATORY BOWEL DISEASE TYPE
6.6.1 CROHN’S DISEASE
6.6.2 ULCERATIVE COLITIS
6.6.3 MICROSCOPIC COLITIS
7 MERGERS AND ACQUISITION
7.1 LICENSING
7.2 COMMERCIALIZATION AGREEMENTS
8 REGULATORY FRAMEWORK
8.1 REGULATORY APPROVAL PROCESS
8.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
8.3 REGULATORY APPROVAL PATHWAYS
8.4 LICENSING AND REGISTRATION
8.5 POST-MARKETING SURVEILLANCE
8.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
9 PIPELINE ANALYSIS
9.1 CLINICAL TRIALS AND PHASE ANALYSIS
9.2 DRUG THERAPY PIPELINE
9.3 PHASE III CANDIDATES
9.4 PHASE II CANDIDATES
9.5 PHASE I CANDIDATES
9.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR GLOBAL ULCERATIVE COLITIS MARKET
Company Name Therapeutic Area
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved But Not Yest Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE
Technology Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR GLOBAL ULCERATIVE COLITIS MARKET
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
10 MARKETED DRUG ANALYSIS
10.1 DRUG
10.1.1 BRAND NAME
10.1.2 GENERICS NAME
10.2 THERAPEUTIC INDIACTION
10.3 PHARACOLOGICAL CLASS OD THE DRUG
10.4 DRUG PRIMARY INDICATION
10.5 MARKET STATUS
10.6 MEDICATION TYPE
10.7 DRUG DOSAGES FORM
10.8 DOSAGES AVAILABILITY
10.9 PACKAGING TYPE
10.1 DRUG ROUTE OF ADMINISTRATION
10.11 DOSING FREQUENCY
10.12 DRUG INSIGHT
10.13 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.
10.13.1 FORECAST MARKET OUTLOOK
10.13.2 CROSS COMPETITION
10.13.3 THERAPEUTIC PORTFOLIO
10.13.4 CURRENT DEVELOPMENT SCENARIO
11 MARKET ACCESS
11.1 10-YEAR MARKET FORECAST
11.2 CLINICAL TRIAL RECENT UPDATES
11.3 ANNUAL NEW FDA APPROVED DRUGS
11.4 DRUGS MANUFACTURER AND DEALS
11.5 MAJOR DRUG UPTAKE
11.6 CURRENT TREATMENT PRACTICES
11.7 IMPACT OF UPCOMING THERAPY
12 R & D ANALYSIS
12.1 COMPARATIVE ANALYSIS
12.2 DRUG DEVELOPMENTAL LANDSCAPE
12.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
12.4 THERAPEUTIC ASSESSMENT
12.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
13 MARKET OVERVIEW
13.1 DRIVERS
13.2 RESTRAINTS
13.3 OPPORTUNITIES
13.4 CHALLENGES
14 GLOBAL ULCERATIVE COLITIS MARKET , SWOT AND DBMR ANALYSIS
15 GLOBAL ULCERATIVE COLITIS MARKET, BY DISEASE TYPE
15.1 OVERVIEW
15.2 ULCERATIVE PROCTITIS
15.3 PROCTOSIGMOIDITIS
15.4 LEFT-SIDED COLITIS
15.5 PANCOLITIS OR UNIVERSAL COLITIS
15.6 FULMINANT COLITIS
16 GLOBAL ULCERATIVE COLITIS MARKET, BY SEVERITY
16.1 OVERVIEW
16.2 MILD
16.3 MODERATE
16.4 SEVERE
17 GLOBAL ULCERATIVE COLITIS MARKET, BY TYPE
17.1 OVERVIEW
17.2 ANTI-INFLAMMATORY DRUGS
17.2.1 CORTICOSTEROIDS
17.2.1.1. PREDNISONE
17.2.1.2. BUDESONIDE
17.2.1.3. HYDROCORTISONE
17.2.1.4. OTHERS
17.2.2 AMINOSALICYLATES
17.2.2.1. SULFASALAZINE
17.2.2.2. MESALAMINE
17.2.2.3. OLSALAZINE
17.2.2.4. BALSALAZIDE
17.2.2.5. OTHERS
17.3 BIOLOGICS
17.3.1 ANTI-TUMOR NECROSIS FACTOR (TNF) AGENTS
17.3.1.1. ADALIMUMAB
17.3.1.2. ADALIMUMAB-ATTO
17.3.1.3. GOLIMUMAB
17.3.1.4. INFLIXIMAB
17.3.2 INTEGRIN RECEPTOR ANTAGONISTS
17.3.3 INTERLEUKIN INHIBITORS
17.3.4 JANUS KINASE (JAK) INHIBITORS
17.4 IMMUNOSUPREESANTS
17.4.1 METHOTREXATE
17.4.2 NATALIZUMAB
17.4.3 VEDOLIZUMAB
17.4.4 AZATHIOPRINE
17.4.5 MERCAPTOPURINE
17.4.6 USTEKINUMAB
17.4.7 OTHERS
17.5 ANTI-DIARRHEAL AGENTS
17.5.1 DIPHENOXYLATE
17.5.2 ATROPINE
17.5.3 LOPERAMIDE
17.5.4 OTHERS
17.6 CALCINEURIN INHIBITORS
17.6.1 TACROLIMUS
17.6.2 CIPROFLOXACIN
17.6.3 METRONIDAZOLE
17.6.4 OTHERS
17.7 OTHERS
18 GLOBAL ULCERATIVE COLITIS MARKET, BY MOLECULES
18.1 OVERVIEW
18.2 BIOLOGICS
18.3 SMALL MOLECULE
19 GLOBAL ULCERATIVE COLITIS MARKET, BY DRUG TYPE
19.1 OVERVIEW
19.2 BRANDED
19.2.1 ENTYVIO
19.2.2 CIMZIA
19.2.3 STELARA
19.2.4 TYSABRI
19.2.5 AVSOLA
19.2.6 OTHERS
19.3 GENERICS
20 GLOBAL ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION
20.1 OVERVIEW
20.2 ORAL
20.3 PARENTERAL
20.4 TOPICAL
20.5 OTHERS (IF ANY)
21 GLOBAL ULCERATIVE COLITIS MARKET, BY POPULATION TYPE
21.1 OVERVIEW
21.2 ADULTS
21.3 PEDIATRICS
21.4 GERIATRICS
22 GLOBAL ULCERATIVE COLITIS MARKET , BY END USER
22.1 OVERVIEW
22.2 HOSPITALS
22.2.1 PUBLIC
22.2.1.1. TIER I
22.2.1.2. TIER II
22.2.1.3. TIER III
22.2.2 PRIVATE
22.2.2.1. TIER I
22.2.2.2. TIER II
22.2.2.3. TIER III
22.3 SPECIALTY CLINICS
22.4 HOME HEALTHCARE
22.5 AMBULATORY CARE CENTERS
22.6 OTHERS
23 GLOBAL ULCERATIVE COLITIS MARKET , BY DISTRIBUTION CHANNEL
23.1 OVERVIEW
23.2 HOSPITAL PHARMACY
23.3 ONLINE PHARAMCY
23.4 RETAIL PHARMACY
23.5 DRUG STORES
23.6 OTHERS
24 GLOBAL ULCERATIVE COLITIS MARKET , COMPANY LANDSCAPE
24.1 COMPANY SHARE ANALYSIS: GLOBAL
24.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
24.3 COMPANY SHARE ANALYSIS: EUROPE
24.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
24.5 MERGERS & ACQUISITIONS
24.6 NEW PRODUCT DEVELOPMENT & APPROVALS
24.7 EXPANSIONS
24.8 REGULATORY CHANGES
24.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
25 GLOBAL ULCERATIVE COLITIS MARKET , BY REGION
Global ULCERATIVE Colitis market , (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
25.1 NORTH AMERICA
25.1.1 U.S.
25.1.2 CANADA
25.1.3 MEXICO
25.2 EUROPE
25.2.1 GERMANY
25.2.2 U.K.
25.2.3 ITALY
25.2.4 FRANCE
25.2.5 SPAIN
25.2.6 RUSSIA
25.2.7 SWITZERLAND
25.2.8 TURKEY
25.2.9 BELGIUM
25.2.10 NETHERLANDS
25.2.11 DENMARK
25.2.12 SWEDEN
25.2.13 POLAND
25.2.14 NORWAY
25.2.15 FINLAND
25.2.16 REST OF EUROPE
25.3 ASIA-PACIFIC
25.3.1 JAPAN
25.3.2 CHINA
25.3.3 SOUTH KOREA
25.3.4 INDIA
25.3.5 SINGAPORE
25.3.6 THAILAND
25.3.7 INDONESIA
25.3.8 MALAYSIA
25.3.9 PHILIPPINES
25.3.10 AUSTRALIA
25.3.11 NEW ZEALAND
25.3.12 VIETNAM
25.3.13 TAIWAN
25.3.14 REST OF ASIA-PACIFIC
25.4 SOUTH AMERICA
25.4.1 BRAZIL
25.4.2 ARGENTINA
25.4.3 REST OF SOUTH AMERICA
25.5 MIDDLE EAST AND AFRICA
25.5.1 SOUTH AFRICA
25.5.2 EGYPT
25.5.3 BAHRAIN
25.5.4 UNITED ARAB EMIRATES
25.5.5 KUWAIT
25.5.6 OMAN
25.5.7 QATAR
25.5.8 SAUDI ARABIA
25.5.9 REST OF MEA
25.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
26 GLOBAL ULCERATIVE COLITIS MARKET , COMPANY PROFILE
26.1 PFIZER INC.
26.1.1 COMPANY OVERVIEW
26.1.2 REVENUE ANALYSIS
26.1.3 GEOGRAPHIC PRESENCE
26.1.4 PRODUCT PORTFOLIO
26.1.5 RECENT DEVELOPMENTS
26.2 TAKEDA PHARMACEUTICALS U.S.A., INC.
26.2.1 COMPANY OVERVIEW
26.2.2 REVENUE ANALYSIS
26.2.3 GEOGRAPHIC PRESENCE
26.2.4 PRODUCT PORTFOLIO
26.2.5 RECENT DEVELOPMENTS
26.3 UCB, INC.
26.3.1 COMPANY OVERVIEW
26.3.2 REVENUE ANALYSIS
26.3.3 GEOGRAPHIC PRESENCE
26.3.4 PRODUCT PORTFOLIO
26.3.5 RECENT DEVELOPMENTS
26.4 JANSSEN BIOTECH, INC.
26.4.1 COMPANY OVERVIEW
26.4.2 REVENUE ANALYSIS
26.4.3 GEOGRAPHIC PRESENCE
26.4.4 PRODUCT PORTFOLIO
26.4.5 RECENT DEVELOPMENTS
26.5 AMGEN INC.
26.5.1 COMPANY OVERVIEW
26.5.2 REVENUE ANALYSIS
26.5.3 GEOGRAPHIC PRESENCE
26.5.4 PRODUCT PORTFOLIO
26.5.5 RECENT DEVELOPMENTS
26.6 ORGANON GROUP OF COMPANIES.
26.6.1 COMPANY OVERVIEW
26.6.2 REVENUE ANALYSIS
26.6.3 GEOGRAPHIC PRESENCE
26.6.4 PRODUCT PORTFOLIO
26.6.5 RECENT DEVELOPMENTS
26.7 CELLTRION HEALTHCARE CO.,LTD.
26.7.1 COMPANY OVERVIEW
26.7.2 REVENUE ANALYSIS
26.7.3 GEOGRAPHIC PRESENCE
26.7.4 PRODUCT PORTFOLIO
26.7.5 RECENT DEVELOPMENTS
26.8 BIOGEN AND SAMSUNG BIOEPIS,
26.8.1 COMPANY OVERVIEW
26.8.2 REVENUE ANALYSIS
26.8.3 GEOGRAPHIC PRESENCE
26.8.4 PRODUCT PORTFOLIO
26.8.5 RECENT DEVELOPMENTS
26.9 BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
26.9.1 COMPANY OVERVIEW
26.9.2 REVENUE ANALYSIS
26.9.3 GEOGRAPHIC PRESENCE
26.9.4 PRODUCT PORTFOLIO
26.9.5 RECENT DEVELOPMENTS
26.1 ELI LILLY AND COMPANY.
26.10.1 COMPANY OVERVIEW
26.10.2 REVENUE ANALYSIS
26.10.3 GEOGRAPHIC PRESENCE
26.10.4 PRODUCT PORTFOLIO
26.10.5 RECENT DEVELOPMENTS
26.11 BRISTOL-MYERS SQUIBB COMPANY
26.11.1 COMPANY OVERVIEW
26.11.2 REVENUE ANALYSIS
26.11.3 GEOGRAPHIC PRESENCE
26.11.4 PRODUCT PORTFOLIO
26.11.5 RECENT DEVELOPMENTS
26.12 F. HOFFMANN-LA ROCHE LTD
26.12.1 COMPANY OVERVIEW
26.12.2 REVENUE ANALYSIS
26.12.3 GEOGRAPHIC PRESENCE
26.12.4 PRODUCT PORTFOLIO
26.12.5 RECENT DEVELOPMENTS
26.13 WARNER CHILCOTT DEUTSCHLAND GMBH
26.13.1 COMPANY OVERVIEW
26.13.2 REVENUE ANALYSIS
26.13.3 GEOGRAPHIC PRESENCE
26.13.4 PRODUCT PORTFOLIO
26.13.5 RECENT DEVELOPMENTS
26.14 LGM PHARMA SOLUTIONS, LLC (DISTRIBUTOR-SALIX PHARMACEUTICALS, A DIVISION OF BAUSCH HEALTH US, LLC)
26.14.1 COMPANY OVERVIEW
26.14.2 REVENUE ANALYSIS
26.14.3 GEOGRAPHIC PRESENCE
26.14.4 PRODUCT PORTFOLIO
26.14.5 RECENT DEVELOPMENTS
26.15 ABBVIE
26.15.1 COMPANY OVERVIEW
26.15.2 REVENUE ANALYSIS
26.15.3 GEOGRAPHIC PRESENCE
26.15.4 PRODUCT PORTFOLIO
26.15.5 RECENT DEVELOPMENTS
26.16 BAYER
26.16.1 COMPANY OVERVIEW
26.16.2 REVENUE ANALYSIS
26.16.3 GEOGRAPHIC PRESENCE
26.16.4 PRODUCT PORTFOLIO
26.16.5 RECENT DEVELOPMENTS
26.17 PROMETHEUS BIOSCIENCES, INC., A SUBSIDIARY OF MERCK & CO., INC
26.17.1 COMPANY OVERVIEW
26.17.2 REVENUE ANALYSIS
26.17.3 GEOGRAPHIC PRESENCE
26.17.4 PRODUCT PORTFOLIO
26.17.5 RECENT DEVELOPMENTS
26.18 INDEX PHARMACEUTICALS HOLDING AB
26.18.1 COMPANY OVERVIEW
26.18.2 REVENUE ANALYSIS
26.18.3 GEOGRAPHIC PRESENCE
26.18.4 PRODUCT PORTFOLIO
26.18.5 RECENT DEVELOPMENTS
26.19 ABIVAX
26.19.1 COMPANY OVERVIEW
26.19.2 REVENUE ANALYSIS
26.19.3 GEOGRAPHIC PRESENCE
26.19.4 PRODUCT PORTFOLIO
26.19.5 RECENT DEVELOPMENTS
26.2 MESOBLAST LIMITED
26.20.1 COMPANY OVERVIEW
26.20.2 REVENUE ANALYSIS
26.20.3 GEOGRAPHIC PRESENCE
26.20.4 PRODUCT PORTFOLIO
26.20.5 RECENT DEVELOPMENTS
26.21 LANDOS BIOPHARMA, INC.
26.21.1 COMPANY OVERVIEW
26.21.2 REVENUE ANALYSIS
26.21.3 GEOGRAPHIC PRESENCE
26.21.4 PRODUCT PORTFOLIO
26.21.5 RECENT DEVELOPMENTS
27 RELATED REPORTS
28 CONCLUSION
29 QUESTIONNAIRE
30 ABOUT DATA BRIDGE MARKET RESEARCH
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
